Furthermore, various outside organizations are involved in research and development activities
for development and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma treatment
drug in the U.S.
Request For Customization of Research Report @ http://bit.ly/2Keuc9h
For instance, in September 2017, Chinese PLA General Hospital, a Chinese government
organization, commenced its clinical trial of Decitabine in combination with SHR – 1210. It is
being used for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody,
while Decitabine is an investigational drug, which is capable of boosting antigen expression.
The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in the
second phase of clinical trials.
Global Hodgkin’s Lymphoma Treatment Market Restraints
Side effects related with drugs used for the treatment of Hodgkin’s lymphoma is expected to
adversely affect adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma
treatment market growth. For instance, according to American Cancer Society, drugs used for
treating Hodgkin’s lymphoma such as doxorubicin and bleomycin can damage heart and lungs
respectively. Hence, such side effects of drugs can hinder the global Hodgkin’s lymphoma
treatment market growth.
Global Hodgkin’s Lymphoma Treatment Market Key Players
Some of the major players operating in the global Hodgkin’s lymphoma treatment market
include Emcure Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals
Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences
Inc., Jansenn Research and Development LLC, and Merck & Co., Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200